BACKGROUND: Inflammation helps regulate normal growth and tissue repair. Although bone morphogenetic proteins (BMPs) and inflammation are known contributors to abnormal bone formation, how these pathways interact in ossification remains unclear. METHODS: We examined this potential link in patients with fibrodysplasia ossificans progressiva (FOP), a genetic condition of progressive heterotopic ossification caused by activating mutations in the Activin A type I receptor (ACVR1/ALK2). FOP patients show exquisite sensitivity to trauma, suggesting that BMP pathway activation may alter immune responses. We studied primary blood, monocyte, and macrophage samples from control and FOP subjects using multiplex cytokine, gene expression, and protein analyses; examined CD14+ primary monocyte and macrophage responses to TLR ligands; and assayed BMP, TGF-β activated kinase 1 (TAK1), and NF-κB pathways. RESULTS: FOP subjects at baseline without clinically evident heterotopic ossification showed increased serum IL-3, IL-7, IL-8, and IL-10. CD14+ primary monocytes treated with the TLR4 activator LPS showed increased CCL5, CCR7, and CXCL10; abnormal cytokine/chemokine secretion; and prolonged activation of the NF-κB pathway. FOP macrophages derived from primary monocytes also showed abnormal cytokine/chemokine secretion, increased TGF-β production, and p38MAPK activation. Surprisingly, SMAD phosphorylation was not significantly changed in the FOP monocytes/macrophages. CONCLUSIONS: Abnormal ACVR1 activity causes a proinflammatory state via increased NF-κB and p38MAPK activity. Similar changes may contribute to other types of heterotopic ossification, such as in scleroderma and dermatomyositis; after trauma; or with recombinant BMP-induced bone fusion. Our findings suggest that chronic antiinflammatory treatment may be useful for heterotopic ossification.
BACKGROUND:Inflammation helps regulate normal growth and tissue repair. Although bone morphogenetic proteins (BMPs) and inflammation are known contributors to abnormal bone formation, how these pathways interact in ossification remains unclear. METHODS: We examined this potential link in patients with fibrodysplasia ossificans progressiva (FOP), a genetic condition of progressive heterotopic ossification caused by activating mutations in the Activin A type I receptor (ACVR1/ALK2). FOP patients show exquisite sensitivity to trauma, suggesting that BMP pathway activation may alter immune responses. We studied primary blood, monocyte, and macrophage samples from control and FOP subjects using multiplex cytokine, gene expression, and protein analyses; examined CD14+ primary monocyte and macrophage responses to TLR ligands; and assayed BMP, TGF-β activated kinase 1 (TAK1), and NF-κB pathways. RESULTS: FOP subjects at baseline without clinically evident heterotopic ossification showed increased serum IL-3, IL-7, IL-8, and IL-10. CD14+ primary monocytes treated with the TLR4 activator LPS showed increased CCL5, CCR7, and CXCL10; abnormal cytokine/chemokine secretion; and prolonged activation of the NF-κB pathway. FOP macrophages derived from primary monocytes also showed abnormal cytokine/chemokine secretion, increased TGF-β production, and p38MAPK activation. Surprisingly, SMAD phosphorylation was not significantly changed in the FOP monocytes/macrophages. CONCLUSIONS: Abnormal ACVR1 activity causes a proinflammatory state via increased NF-κB and p38MAPK activity. Similar changes may contribute to other types of heterotopic ossification, such as in scleroderma and dermatomyositis; after trauma; or with recombinant BMP-induced bone fusion. Our findings suggest that chronic antiinflammatory treatment may be useful for heterotopic ossification.
Entities:
Keywords:
Bone Biology; Bone disease; Cellular immune response; Genetic diseases; Inflammation
Authors: Sarah Kim; Jessica Becker; Matthias Bechheim; Vera Kaiser; Mahdad Noursadeghi; Nadine Fricker; Esther Beier; Sven Klaschik; Peter Boor; Timo Hess; Andrea Hofmann; Stefan Holdenrieder; Jens R Wendland; Holger Fröhlich; Gunther Hartmann; Markus M Nöthen; Bertram Müller-Myhsok; Benno Pütz; Veit Hornung; Johannes Schumacher Journal: Nat Commun Date: 2014-10-20 Impact factor: 14.919
Authors: Benjamin K Potter; Travis C Burns; Anton P Lacap; Robert R Granville; Donald A Gajewski Journal: J Bone Joint Surg Am Date: 2007-03 Impact factor: 5.284
Authors: Hsiao Hsin Sung Hsieh; Michael T Chung; Ronald M Allen; Kavitha Ranganathan; Joe Habbouche; David Cholok; Jonathan Butts; Arminder Kaura; Ramkumar Tiruvannamalai-Annamalai; Chris Breuler; Caitlin Priest; Shawn J Loder; John Li; Shuli Li; Jan Stegemann; Steven L Kunkel; Benjamin Levi Journal: Front Endocrinol (Lausanne) Date: 2017-04-24 Impact factor: 5.555
Authors: Petronela Ancuta; Ravi Rao; Ashlee Moses; Andrew Mehle; Sunil K Shaw; F William Luscinskas; Dana Gabuzda Journal: J Exp Med Date: 2003-06-16 Impact factor: 14.307
Authors: Xiaobing Yu; Amy N Ton; Zejun Niu; Blanca M Morales; Jiadong Chen; Joao Braz; Michael H Lai; Emilie Barruet; Hongju Liu; Kin Cheung; Syed Ali; Tea Chan; Katherine Bigay; Jennifer Ho; Ina Nikolli; Steven Hansberry; Kelly Wentworth; Arnold Kriegstein; Allan Basbaum; Edward C Hsiao Journal: Pain Date: 2022-04-20 Impact factor: 7.926
Authors: Celia L Gregson; Dylan J M Bergen; Paul Leo; Richard B Sessions; Lawrie Wheeler; April Hartley; Scott Youlten; Peter I Croucher; Aideen M McInerney-Leo; William Fraser; Jonathan Cy Tang; Lisa Anderson; Mhairi Marshall; Leon Sergot; Lavinia Paternoster; George Davey Smith; Matthew A Brown; Chrissy Hammond; John P Kemp; Jon H Tobias; Emma L Duncan Journal: J Bone Miner Res Date: 2019-11-14 Impact factor: 6.390
Authors: Koji Matsuo; Abigail Lepinski; Robert D Chavez; Emilie Barruet; Ashley Pereira; Tania A Moody; Amy N Ton; Aditi Sharma; Judith Hellman; Kiichiro Tomoda; Mary C Nakamura; Edward C Hsiao Journal: Bone Date: 2021-07-24 Impact factor: 4.398